ArticleCurrent urology2026
Cancer-specific mortality of grade group 1 prostate cancer: Results from Surveillance, Epidemiology, and End Results Database, 2004-2021.
Article in Current urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Background: The nomenclature designation of grade group (GG) 1 prostate cancer (PCa) as "cancer" has recently become controversial because of its generally indolent clinical course and the associated psychological burden, which may contribute to overtreatment. We aimed to investigate PCa-specific mortality (PCSM) among patients with GG1 PCa using the Surveillance, Epidemiology, and End Results database with extended follow-up. Materials and methods: Patients diagnosed with GG1 prostatic adenocarcinoma between 2004 and 2021 were enrolled. From 2010 to 2021, GG1 disease was identified as Gleason Score ≤6, whereas from 2004 to 2009, it was classified as well-differentiated (Gleason Score 2-4) and moderately differentiated (Gleason Score 5-6) PCa. Only patients with available follow-up information were included. Because death from other causes represents a potential competing event of the primary outcome of PCSM, we conducted competing-risk analyses to evaluate cumulative mortality and assessed factors associated with PCSM using competing-risk regression models. Results: In total, 240,966 patients with GG1 PCa aged ≥30 years were identified. With a median follow-up of 10.1 years, 5086 patients (2.1%) died of PCa, and 34,168 patients (14.2%) died of other causes. Factors associated with worse PCSM included old age (subdistribution hazard ratios [SHR], 1.06 per year; 95% confidence interval [CI], 1.05-1.06), Black race (reference: White; SHR, 1.28; 95% CI, 1.18-1.39), Hispanic ethnicity (SHR, 1.11; 95% CI, 1.01-1.22), unmarried status (SHR, 1.34; 95% CI, 1.25-1.44), high prostate-specific antigen level (SHR, 1.02 per 0.1 ng/mL; 95% CI, 1.02-1.02), and locally advanced T stage ≥3 (reference: T ≤2; SHR, 2.18; 95% CI, 1.82-2.61). Conversely, radical prostatectomy (SHR, 0.35; 95% CI, 0.32-0.39), radiation therapy (SHR, 0.85; 95% CI, 0.80-0.91), and high household income (SHR, 0.95 per $10,000; 95% CI, 0.93-0.96) were associated with lower observed PCSM. Conclusions: Although GG1 PCa is typically indolent, 5086 patients died of PCa during extended follow-up. These findings support the continued classification of GG1 disease as "cancer," with vigilant active surveillance to detect disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.